Prospective Associations of Hemoglobin A and C-peptide with Risk of Diabetes-related Cancers in the Cancer Prevention Study-II Nutrition Cohort
Overview
Authors
Affiliations
Self-reported type 2 diabetes mellitus (T2DM) is a risk factor for many cancers, suggesting its pathology relates to carcinogenesis. We conducted a case-cohort study to examine associations of hemoglobin A (HbA) and c-peptide with cancers associated with self-reported T2DM. This study was drawn from a prospective cohort of 32,383 women and men who provided blood specimens at baseline: c-peptide and HbA were assessed in 3,000 randomly selected participants who were cancer-free-at-baseline and an additional 2,281 participants who were cancer-free-at-baseline and subsequently diagnosed with incident colorectal, liver, pancreatic, female breast, endometrial, ovarian, bladder, or kidney cancers. Weighted-Cox regression models estimated hazards ratios (HRs) and 95% confidence intervals (CI), adjusted for covariates. C-peptide was associated with higher risk of liver cancer (per standard deviation (SD) HR: 1.80; 95%CI: 1.32-2.46). HbA was associated with higher risk of pancreatic cancer (per SD HR: 1.21 95%CI 1.05-1.40) and with some suggestion of higher risks for all-cancers-of-interest (per SD HR: 1.05; 95%CI: 0.99-1.11) and colorectal (per SD HR: 1.09; 95%CI: 0.98-1.20), ovarian (per SD HR: 1.18; 95%CI 0.96-1.45) and bladder (per SD HR: 1.08; 95%CI 0.96-1.21) cancers. Compared to no self-reported T2DM and HbA <6.5% (reference group), self-reported T2DM and HbA <6.5% (i.e., T2DM in good glycemic control) was not associated with risk of colorectal cancer, whereas it was associated with higher risks of all-cancers-of-interest combined (HR: 1.28; 95%CI: 1.01-1.62), especially for breast and endometrial cancers. Additional large, prospective studies are needed to further explore the roles of hyperglycemia, hyperinsulinemia, and related metabolic traits with T2DM-associated cancers to better understand the mechanisms underlying the self-reported T2DM-cancer association and to identify persons at higher cancer risk.
Prospective Analysis of Circulating Biomarkers and Ovarian Cancer Risk in the UK Biobank.
Sasamoto N, Hathaway C, Townsend M, Terry K, Trabert B, Tworoger S Cancer Epidemiol Biomarkers Prev. 2024; 33(10):1347-1355.
PMID: 39007864 PMC: 11446659. DOI: 10.1158/1055-9965.EPI-24-0319.
Natalicchio A, Marrano N, Montagnani M, Gallo M, Faggiano A, Zatelli M J Endocrinol Invest. 2024; 47(12):2915-2928.
PMID: 38935200 PMC: 11549129. DOI: 10.1007/s40618-024-02417-z.
Prediabetes and the risk of breast cancer: a meta-analysis.
Lin J, Tu R, Lu Z Front Oncol. 2023; 13:1238845.
PMID: 37790752 PMC: 10544966. DOI: 10.3389/fonc.2023.1238845.